Ep. 195: Jim Roppel: Stock Market Lessons Of 2022
Investing With IBD
Sena Corps Blows Up on FDA Victory
There's a gaggle of not golden geese, but there's about 15 Biotechs that have a market cap between 500 million and 2 billion. This has earnings. All those others are minefields. They are disasters. I spent six or nine months building this whole position at all, but it all went up in flames. Anything without earnings in biotech is subject to a bad clinical trial on,. You know, that's the non performance. And they're super illiquid time. They're little lotto tickets.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
